Furthermore, we found AMPK activity is inhibited in patients with pancreatic ductal adenocarcinoma (PDAC) with high ECM stiffness and is associated with a poor survival outcome. Here, PRKAA2 is linked to pancreatic ductal adenocarcinoma.